Fortis Capital Advisors LLC Buys Shares of 10,468 Edwards Lifesciences Corporation $EW

Fortis Capital Advisors LLC purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 10,468 shares of the medical research company’s stock, valued at approximately $892,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Earned Wealth Advisors LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth approximately $234,000. Hedges Asset Management LLC purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth $332,000. Bayforest Capital Ltd boosted its holdings in shares of Edwards Lifesciences by 37.8% during the fourth quarter. Bayforest Capital Ltd now owns 2,990 shares of the medical research company’s stock worth $255,000 after purchasing an additional 820 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its holdings in shares of Edwards Lifesciences by 1.8% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 19,453 shares of the medical research company’s stock worth $1,658,000 after purchasing an additional 348 shares during the last quarter. Finally, Lecap Asset Management Ltd. purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $1,071,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 24,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the transaction, the vice president directly owned 21,266 shares of the company’s stock, valued at $1,782,941.44. The trade was a 53.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $80.98, for a total transaction of $82,518.62. Following the sale, the vice president owned 33,934 shares of the company’s stock, valued at approximately $2,747,975.32. This represents a 2.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 86,058 shares of company stock worth $7,118,636. Company insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the subject of several analyst reports. Stifel Nicolaus set a $110.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. TD Cowen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Mizuho set a $95.00 price target on Edwards Lifesciences and gave the company an “outperform” rating in a report on Monday, April 13th. Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, January 12th. Finally, BTIG Research reiterated a “buy” rating and set a $103.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $95.74.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $81.50 on Tuesday. The firm has a market capitalization of $46.99 billion, a PE ratio of 44.53, a P/E/G ratio of 2.11 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The business has a 50-day moving average of $81.37 and a two-hundred day moving average of $82.16. Edwards Lifesciences Corporation has a 12 month low of $68.63 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. During the same period in the prior year, the firm earned $0.59 earnings per share. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, research analysts forecast that Edwards Lifesciences Corporation will post 2.96 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.